What are the indications, dosing, and titration recommendations for vasopressor therapy in a patient with shock and persistent hypotension (mean arterial pressure <65 mm Hg) despite adequate fluid resuscitation?

Vasopressor Therapy in Shock with Persistent Hypotension

Start norepinephrine immediately as the first-line vasopressor to target a mean arterial pressure (MAP) of ≥65 mmHg in patients with persistent hypotension despite adequate fluid resuscitation 1, 2.

Initial Vasopressor Selection and Dosing

Norepinephrine is unequivocally the first-choice vasopressor across all major guidelines 1, 2. The evidence supporting this is robust, with moderate quality evidence from the Surviving Sepsis Campaign 2 and reinforced by the most recent 2025 ESICM guidelines 1.

Starting Norepinephrine:

• Initiate early - do not delay while continuing futile fluid administration in non-fluid-responsive patients 3, 4
• Initial dosing: Start at 0.01-0.05 mcg/kg/min and titrate upward
• Target MAP: Initially target ≥65 mmHg 1, 2
• Route: Peripheral IV administration through a 20-gauge or larger line is safe and effective while establishing central access 3

Critical Pitfall:

The most common error is delaying vasopressor initiation while administering excessive fluids. Once a patient demonstrates persistent hypotension after initial fluid resuscitation (typically 30 mL/kg crystalloid), vasopressors should be started promptly 2, 3.

Individualizing MAP Targets

While 65 mmHg is the initial target, the 2025 ESICM guidelines explicitly recommend individualizing blood pressure targets 1:

• Chronic hypertension: Consider higher MAP targets (70-80 mmHg) if clinical improvement is observed 1, 2
• High CVP values: May benefit from higher MAP targets if showing clinical improvement 1
• Traumatic hemorrhagic shock: Tolerate lower MAP (50-60 mmHg, SBP 80-90 mmHg) until bleeding is controlled, UNLESS traumatic brain injury is present 1
• Traumatic brain injury (GCS ≤8): Target MAP ≥80 mmHg 1

Adding Second-Line Vasopressors

When to Add Vasopressin:

Add vasopressin when norepinephrine reaches 0.25-0.50 mcg/kg/min - this is the most common practice threshold identified in international surveys 5, though emerging evidence suggests earlier initiation may be beneficial 4.

• Dose: 0.03 units/min (fixed dose, not titrated) 2, 5
• Purpose: Catecholamine-sparing effect and complementary vasoconstriction mechanism 2, 6
• Evidence: Moderate quality evidence supports adding vasopressin to raise MAP or decrease norepinephrine requirements 2

Important Distinction:

Vasopressin should NOT be used as a single initial vasopressor - it is strictly an add-on therapy 2. Doses higher than 0.03-0.04 units/min should be reserved for salvage therapy only 2.

When to Add Epinephrine:

If MAP remains inadequate despite norepinephrine plus vasopressin, add epinephrine (weak recommendation, low quality evidence) 2. This is particularly relevant when cardiac dysfunction coexists with vasodilatory shock 2, 7.

Alternative Agents (Limited Indications)

• Dopamine: Only in highly selected patients with low risk of tachyarrhythmias and absolute/relative bradycardia 2. NOT recommended for renal protection 2
• Dobutamine: Add when evidence of persistent hypoperfusion despite adequate vasopressor support, particularly with myocardial dysfunction 2
• Angiotensin II: May be considered in profoundly hypotensive, norepinephrine-refractory patients 8

Monitoring and Titration Strategy

Arterial Pressure Monitoring:

Insert an arterial catheter in shock not responsive to initial therapy and/or requiring vasopressor infusion 1. This is a best practice statement from the 2025 ESICM guidelines.

Titration Approach:

• Titrate vasopressors to achieve individualized MAP target
• Monitor for clinical improvement: mental status, capillary refill time, lactate clearance, urine output 3
• Avoid excessive vasoconstriction causing organ ischemia 8

Weaning Strategy:

• Begin tapering when MAP is stable above target 5
• 88% of clinicians use MAP level to trigger tapering 5
• Wean progressively (89% of practitioners) 5
• When combining norepinephrine and vasopressin, reduce norepinephrine first before discontinuing vasopressin 5, 6

Contraindications and Cautions

Vasopressin contraindications include:

• Non-occlusive mesenteric ischemia 5
• Digital or skin ischemia 5

General vasopressor cautions:

• Risk of excessive vasoconstriction and organ ischemia
• Tachycardia and tachyarrhythmias (particularly with high-dose catecholamines)
• Hyperglycemia and hyperlactatemia 8

Refractory Shock Considerations

For refractory septic shock despite adequate vasopressor therapy, consider adding hydrocortisone (some evidence shows mortality benefit in specific trials) 3. The 2025 guidelines also mention corticosteroids for refractory shock 7.

The evidence strongly supports a structured approach: norepinephrine first, vasopressin second at moderate norepinephrine doses, and epinephrine third if needed, with individualized MAP targets based on patient-specific factors rather than rigid adherence to 65 mmHg for all patients 1, 2, 4.